5-Amino-1MQ and genetics: what the evidence actually supports

What's this video probably claiming?

Based on the caption and hashtag cluster, this video almost certainly argues that individual genetic variation, likely referencing NNMT gene expression or methylation-related SNPs, affects how well someone responds to 5-Amino-1MQ, a small-molecule NNMT inhibitor. The creator appears to recommend cycling the compound, supporting methylation pathways alongside it, and pairing it with berberine, L-carnitine, and NAD+ precursors. She's also likely tying response variability to metabolic phenotype, possibly referencing fat mass distribution or insulin sensitivity as outcome markers. The framing here is classic precision biohacking: your DNA tells you how to dose, stack, and time this compound. That sounds compelling. It's also almost entirely speculative given where the published research on 5-Amino-1MQ actually sits right now.

What does the science actually show?

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates methyl group metabolism and has been linked to adipogenesis and energy expenditure. The most-cited preclinical work comes from Kannt et al. (2018, Scientific Reports) and Neelakantan et al. (2018, Nature Communications), where NNMT inhibition in mouse models reduced fat mass and improved metabolic markers without caloric restriction. In the Neelakantan study, high-fat-diet mice receiving 5-Amino-1MQ showed roughly 7% reductions in fat mass over several weeks. Those are rodent results at controlled doses in controlled conditions. There are no published randomized controlled trials in humans. No peer-reviewed pharmacokinetic data in humans. No published dose-response curves for people. The genetic personalization angle, the idea that your NNMT SNPs or MTHFR status should guide your protocol, has zero published evidence behind it.

Where does the social media noise diverge from clinical reality?

The stack being recommended here combines 5-Amino-1MQ with berberine, L-carnitine, and NAD+ precursors. Each of these has its own evidence base. Berberine has modest RCT support for glucose regulation (Yin et al., 2008, Metabolism). L-carnitine shows mixed results for fat oxidation in meta-analyses (Pooyandjoo et al., 2016, Obesity Reviews). NAD+ precursors like NMN have emerging but still limited human data (Yoshino et al., 2021, Science). The problem is that combining compounds with overlapping effects on methylation and NAD+ metabolism is not a studied strategy. It is a theory. The creator's genetics framing also implies that consumer genotyping data, think 23andMe-level SNP panels, can guide peptide dosing. That claim has no validated clinical framework behind it. Nutrigenomics research does not currently support individualized peptide stacking based on direct-to-consumer genetic reports.

What should you actually know?

5-Amino-1MQ is not FDA-approved and has no established human safety profile in peer-reviewed literature. It is sometimes compounded and sold through peptide vendors, but that does not make it studied or regulated. The cycling recommendation in the caption may reflect a reasonable precautionary instinct, since NNMT inhibition does affect methyl group availability systemically, but there is no published guidance on optimal cycle length, washout periods, or who should avoid this compound. People with pre-existing methylation disorders, liver conditions, or who are taking drugs metabolized through related pathways face unknown interaction risks. The disclaimer at the end of the caption is cut off, which is not reassuring. If you are being told that your genetics unlock how to take an unstudied compound, that is a marketing framing, not a clinical one.